TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of "Buy" from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has earned an average rating of "Buy" from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.56.

A number of equities research analysts recently issued reports on TLSI shares. Roth Mkm reissued a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price objective on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday. Finally, Lake Street Capital started coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective for the company.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock traded up $0.12 on Tuesday, hitting $5.62. The company had a trading volume of 16,018 shares, compared to its average volume of 42,966. The stock has a 50-day moving average of $5.40 and a 200-day moving average of $4.74. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.42. The firm has a market capitalization of $171.37 million, a P/E ratio of -2.26 and a beta of 0.48.

Remove Ads

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.35). The company had revenue of $8.26 million during the quarter, compared to analyst estimates of $8.12 million. Equities analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, insider Sean Murphy acquired 15,000 shares of the business's stock in a transaction on Monday, January 27th. The stock was purchased at an average price of $5.31 per share, with a total value of $79,650.00. Following the acquisition, the insider now directly owns 182,732 shares of the company's stock, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Emmett Young purchased 24,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average cost of $5.40 per share, with a total value of $129,600.00. Following the purchase, the chief financial officer now owns 24,000 shares of the company's stock, valued at $129,600. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 54,856 shares of company stock worth $294,608 in the last ninety days. 32.80% of the stock is owned by company insiders.

Institutional Trading of TriSalus Life Sciences

Large investors have recently made changes to their positions in the company. Walleye Capital LLC bought a new stake in TriSalus Life Sciences during the third quarter worth $66,000. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $184,000. Vestcor Inc acquired a new stake in TriSalus Life Sciences in the third quarter valued at about $108,000. Geode Capital Management LLC boosted its stake in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after buying an additional 62,542 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in TriSalus Life Sciences in the third quarter valued at about $92,000. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.